NASDAQ:ATHX - Athersys Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.03 -0.03 (-1.46 %)
(As of 07/16/2018 02:13 PM ET)
Previous Close$2.08
Today's Range$2.01 - $2.08
52-Week Range$1.29 - $3.09
Volume12,849 shs
Average Volume866,156 shs
Market Capitalization$284.20 million
P/E Ratio-7.00
Dividend YieldN/A
Athersys logoAthersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase II study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase II clinical study for treating patients with acute myocardial infarction; and, which is in Phase I/II clinical study for treating patients with acute respiratory distress syndrome, as well as that has completed Phase I clinical study for patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical need. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke in Japan; RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; the University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.

Receive ATHX News and Ratings via Email

Sign-up to receive the latest news and ratings for ATHX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio5.05
Quick Ratio5.05


Trailing P/E Ratio-7.00
Forward P/E Ratio-8.46
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.71 million
Price / Sales75.49
Cash FlowN/A
Price / CashN/A
Book Value$0.20 per share
Price / Book10.15


EPS (Most Recent Fiscal Year)($0.29)
Net Income$-32,240,000.00
Net Margins-1,112.74%
Return on Equity-119.58%
Return on Assets-92.10%


Outstanding Shares137,960,000
Market Cap$284.20

The Truth About Cryptocurrencies

Athersys (NASDAQ:ATHX) Frequently Asked Questions

What is Athersys' stock symbol?

Athersys trades on the NASDAQ under the ticker symbol "ATHX."

How were Athersys' earnings last quarter?

Athersys, Inc. (NASDAQ:ATHX) released its quarterly earnings data on Thursday, May, 10th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01. The biopharmaceutical company earned $1.07 million during the quarter, compared to analyst estimates of $1.17 million. Athersys had a negative net margin of 1,112.74% and a negative return on equity of 119.58%. View Athersys' Earnings History.

When is Athersys' next earnings date?

Athersys is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Athersys.

What price target have analysts set for ATHX?

1 brokers have issued twelve-month target prices for Athersys' stock. Their predictions range from $6.00 to $6.00. On average, they anticipate Athersys' share price to reach $6.00 in the next twelve months. This suggests a possible upside of 195.6% from the stock's current price. View Analyst Ratings for Athersys.

What is the consensus analysts' recommendation for Athersys?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Athersys stock?

Here are some recent quotes from research analysts about Athersys stock:
  • 1. According to Zacks Investment Research, "Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company's lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity. The company is also developing other orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE). Athersys is developing MultiStem(r), its patented, adult-derived ``off the shelf'' stem cell product platform, for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications. " (7/11/2018)
  • 2. Maxim Group analysts commented, "Athersys and the University of Texas Health Science Center at Houston (UTHealth) announced plans to initiate a P2 study of MultiStem for the treatment and prevention of complications after severe traumatic injury. $3.5M in grant funding will be used to support the study." (4/23/2018)

Who are some of Athersys' key competitors?

Who are Athersys' key executives?

Athersys' management team includes the folowing people:
  • Mr. William B. J. Lehmann Jr., Pres, COO & Sec. (Age 52)
  • Dr. John J. Harrington, Co-Founder, Chief Scientific Officer, Exec. VP & Director (Age 51)
  • Ms. Laura K. Campbell, Sr. VP of Fin. (Age 54)
  • Dr. Gil Van Bokkelen, Co-Founder, Chairman & CEO (Age 57)
  • Dr. Manal Morsy M.D., PH.D., Sr. VP & Head of Global Regulatory Affairs

Has Athersys been receiving favorable news coverage?

Media headlines about ATHX stock have trended positive on Monday, Accern Sentiment reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Athersys earned a media sentiment score of 0.43 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 47.48 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Athersys?

Shares of ATHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Athersys' stock price today?

One share of ATHX stock can currently be purchased for approximately $2.03.

How big of a company is Athersys?

Athersys has a market capitalization of $284.20 million and generates $3.71 million in revenue each year. The biopharmaceutical company earns $-32,240,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. Athersys employs 66 workers across the globe.

How can I contact Athersys?

Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The biopharmaceutical company can be reached via phone at 216-431-9900 or via email at [email protected]

MarketBeat Community Rating for Athersys (NASDAQ ATHX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  216 (Vote Outperform)
Underperform Votes:  158 (Vote Underperform)
Total Votes:  374
MarketBeat's community ratings are surveys of what our community members think about Athersys and other stocks. Vote "Outperform" if you believe ATHX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATHX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.